Michael Burkes Brophy, Chief Financial Officer of Natera Inc (NASDAQ: NTRA), divested a total of 60,723 shares of the company's common stock over two days, January 20 and 21, 2026. These transactions collectively amounted to around $14.6 million, with share prices fluctuating between $234.7384 and $242.6685 during the sales period.
On January 20, Brophy sold 23,948 shares at $234.7384 each. The following day, January 21, he sold an additional 602 shares at $235 per share and 36,573 shares at the top range price of $242.6685. Additionally, on January 20, Brophy exercised 1,522 Restricted Stock Units (RSUs) which were recorded at a value of zero for that exercise.
Alongside these insider trading activities, Natera disclosed robust preliminary financial results for the fourth quarter of 2025. The company's revenues are projected to have grown by nearly 40% year-over-year, surpassing analysts’ expectations. This strong performance coincided with a 17% rise in test volume during the period, pointing towards increased demand for Natera's diagnostic offerings.
Reflecting confidence in the company's outlook, Canaccord Genuity sustained its Buy rating for Natera shares, setting a target price at $285.00. The company also announced a significant collaboration with Exelixis Inc. for a phase 3 clinical trial focused on colorectal cancer patients. Utilizing Natera’s Signatera test, the study intends to identify molecular residual disease to inform trial enrollment.
In addition, Natera unveiled a new multi-modal artificial intelligence model designed to augment cancer recurrence risk assessment. This model integrates diverse data sources including longitudinal circulating tumor DNA (ctDNA) and digital pathology imaging to improve the predictive capacity of the Signatera minimal residual disease (MRD) test.
Further underscoring the clinical relevance of its testing technologies, Natera’s Signatera test was featured in a peer-reviewed study published in JAMA Oncology. The research indicated that colorectal cancer patients with detectable ctDNA post-surgery demonstrated improved survival outcomes when treated with a combination of celecoxib and chemotherapy.
Looking ahead, Natera is preparing to present findings from its EXPAND clinical trial at the February 2026 Society for Maternal-Fetal Medicine meeting. This trial evaluates the Fetal Focus screening test, which detects inherited disease-causing genetic variants in fetuses, spotlighting Natera’s expanding role in both oncology and prenatal genetic testing.
These developments signify Natera’s steady progression in advancing genetic diagnostic tools, enhancing cancer patient management, and broadening its research collaborations to support evidence-based clinical applications.